Conjugated linoleic acid modulates immune responses in patients with mild to moderately active Crohn's disease

Clinical Nutrition

Volumn 31, Issue 5, 2012, Pages 721-727

  Bassaganya Riera, Josep ^a   Hontecillas, Raquel ^a   Horne, William T ^a   Sandridge, Mikki ^b   Herfarth, Hans H ^b   Bloomfeld, Richard ^c   Isaacs, Kim L ^b  

^a VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Conjugated linoleic acid; Immunoregulation; Inflammatory bowel disease; Peroxisome proliferator activated receptor

Indexed keywords

CONJUGATED LINOLEIC ACID; GAMMA INTERFERON; INTERLEUKIN 17; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; LYMPHOCYTE PROLIFERATION; MALE; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; QUALITY OF LIFE; QUESTIONNAIRE;

ADMINISTRATION, ORAL; ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROHN DISEASE; FEMALE; HUMANS; IMMUNITY; INTERFERON-GAMMA; INTERLEUKIN-17; LEUKOCYTES, MONONUCLEAR; LINOLEIC ACIDS, CONJUGATED; MALE; MIDDLE AGED; PILOT PROJECTS; PPAR GAMMA; QUALITY OF LIFE; QUESTIONNAIRES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866613234     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2012.03.002     Document Type: Article

References (41)

1. Marks D. Defective innate immunity in inflammatory bowel disease: a crohn's disease exclusivity?. Curr Opin Gastroenterol 2011, 27:328-334.
2. Ioaddnidis O., Varnalidis I., Paraskevas G., Botsios D. Nutritional modulation of the inflammatory bowel response. Digestion 2011, 84:89-101.
3. Bassaganya-Riera J., Hontecillas R. Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care 2010, 13:569-573.
4. Huebner S., Campbell J., Butz D., Fulmer T., Gendron-Fitzpatrick A., Cook M. Individual isomers of conjugated linoleic acid reduce inflammation associated with established collagen-induced arthritis in dba/1 mice. J Nutr 2010, 140:1454-1461.
5. Ishiguro K., Oku H., Suitani A., Yamamoto Y. Effects of conjugated linoleic acid on anaphylaxis and allergic pruritus. Biol Pharm Bull 2002, 25:1655-1657.
6. Hontecillas R., Wannemeulher M., Zimmerman D., Hutto D., Wilson J., Ahn D., et al. Nutritional regulation of porcine bacterial-induced colitis by conjugated linoleic acid. J Nut 2002, 132:2019-2027.
7. Bassaganya-Riera J., Reynolds K., Martino-Catt S., Cui Y., Hennighausen L., Gonzalez F., et al. Activation of ppar gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 2004, 127:777-791.
8. Bassaganya-Riera J., Hontecillas R. Cla and n-3 pufa differentially modulate clinical activity and colonic ppar-responsive gene expression in a pig model of experimental ibd. Clin Nutr 2006, 25:454-465.
9. Evans N., Misyak S., Schmelz E., Guri A., Hontecillas R., Bassaganya-Riera J. Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of ppargamma. J Nutr 2010, 140:515-521.
10. McNeel R., Smith E., Mersmann H. Isomers of conjugated linoleic acid modulate human preadipocyte differentiation. Vitro Cell Dev Biol Anim 2003, 39(8-9):375-382. 2003;39:375-82.
11. Meadus W., MacInnis R., Dugan M. Prolonged dietary treatment with conjugated linoleic acid stimulates porcine muscle peroxisome proliferator activated receptor gamma and glutamine-fructose aminotransferase gene expression in vivo. J Mol Endocrinol 2002, 28:79-86.
12. Kohno H., Yasui Y., Suzuki R., Hosokawa M., Miyashita K., Tanaka T. Dietary seed oil rich in conjugated linolenic acid from bitter melon inhibits azoxymethane-induced rat colon carcinogenesis through elevation of colonic ppargamma expression and alteration of lipid composition. Int J Cancer 2004, 110:896-901.
13. Yu Y., Correll P., Vanden Heuvel J. Conjugated linoleic acid decreases production of pro-inflammatory products in macrophages: evidence for a ppar gamma-dependent mechanism. Biochim Biophys Acta 2002, 1581:89-99.
14. Yang M., Cook M. Dietary conjugated linoleic acid decreased cachexia, macrophage tumor necrosis factor-alpha production, and modifies splenocyte cytokines production. Exp Biol Med 2003, 228:51-58.
15. Kennedy A., Chung S., LaPoint K., Fabiyi O., McIntosh M.K. Trans-10, cis-12 conjugated linoleic acid antagonizes ligand-dependent ppargamma activity in primary cultures of human adipocytes. J Nutr 2008, 138:455-461.
16. Miller J.R., Siripurkpong P., Hawes J., Majdalawieh A., Ro H.S., McLeod R.S. The trans-10, cis-12 isomer of conjugated linoleic acid decreases adiponectin assembly by ppargamma-dependent and ppargamma-independent mechanisms. J Lipid Res 2008, 49:550-562.
17. Brandebourg T., Hu C. Isomer-specific regulation of differentiating pig preadipocytes by conjugated linoleic acids. J Anim Sci 2005, 83:2096-2105.
18. Bassaganya-Riera J., Viladomiu M., Pedragosa M., De Simone C., Carbo A., Shaykhutdinov R., et al. Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage ppar gamma to suppress colitis. PLoS One 2012, 7:E31238.
19. Rousseaux C., Lefebvre B., Dubuquoy L., Lefebvre P., Romano O., Auwerx J., et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 2005, 201:1205-1215.
20. Lewis J., Lichtenstein G., Deren J., Sands B., Hanauer S., Katz J., et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 2008, 134:688-695.
21. Palee S., Chattipakorn S., Phrommintikul A., Chattipakorn N. Pparγ activator, rosiglitazone: is it beneficial or harmful to the cardiovascular system?. World J Cardiol 2011, 26:144-152.
22. Bassaganya-Riera J., Hontecillas R., Zimmerman D., Wannemuehler M. Dietary conjugated linoleic acid modulates phenotype and effector functions of porcine cd8(+) lymphocytes. J Nutr 2001, 131:2370-2377.
23. Bassaganya-Riera J., Pogranichniy R., Jobgen S., Halbur P., Yoon K., O'Shea M., et al. Conjugated linoleic acid ameliorates viral infectivity in a pig model of virally induced immunosuppression. J Nutr 2003, 133:3204-3214.
24. Bassaganya-Riera J., Hontecillas R., Zimmerman D., Wannemeulher M. Long-term influence of lipid nutrition on the induction of cd8(+) responses to viral or bacterial antigens. Vaccine 2002, 20:1435-1444.
25. Albers R., van der Wielen R., Brink E., Hendriks H., Dorovska-Taran V., Mohede I. Effects of cis-9, trans-11 and trans-10, cis-12 conjugated linoleic acid (cla) isomers on immune function in healthy men. Eur J Clin Nutr 2003, 57:495-603.
26. Best W., Becktel J., Singleton J., Kern F. Development of a crohn's disease activity index. National cooperative crohn's disease study. Gastroenterology 1976, 70:493-494.
27. Irvine E., Feagan B., Rochon J., Archambault A., Fedorak R., Groll A., et al. Quality of life: a valid and reliable measure of therpeutic efficacy in the treatment of inflammatory bowel disease: Canadian crohn's relapse prevention trial study group. Gastroenterology 1994, 106:287-296.
28. Bassaganya-Riera J., Guri A., Noble A., Reynolds K., King J., Wood C., et al. Arachidonic acid-and docosahexaenoic acid-enriched formulas modulate antigen-specific t cell responses to influenza virus in neonatal piglets. Am J Clin Nutr 2007, 85:824-836.
29. Bassaganya-Riera J., Guri A., Lu P., Climent M., Carbo A., Sobral B., et al. Abscisic acid regulates inflammation via ligand-binding domain-independent activation of peroxisome proliferator-activated receptor gamma. J Biol Chem 2011, 286:2504-2516.
30. De Vroey B., Colombel J. Ibd in 2010: optimizing treatment and minimizing adverse events. Nat Rev Gastroenterol Hepatol 2011, 8:74-76.
31. Clarke J.O., Mullin G.E. A review of complementary and alternative approaches to immunomodulation. Nutr Clin Pract 2008, 23:49-62.
32. Kong S., Hurlstone D., Pocock C., Walkington L., Farquharson N., Bramble M., et al. The incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J Clin Gastroenterol 2005, 39:138-141.
33. Whigham L., O'Shea M., Mohede I., Walaski H., Atkinson R. Safety profile of conjugated linoleic acid in a 12-month trial in obese humans. Food Chem Toxicol 2004, 42:1701-1709.
34. Whigham L., Cook E., Stahl J., Saban R., Bjorling D., Pariza M., et al. Cla reduces antigen-induced histamine and pge(2) release from sensitized guinea pig tracheae. Am J Physiol Regul Integr Comp Physiol 2001, 280:R908-R912.
35. Whigham L., Higbee A., Bjorling D., Park Y., Pariza M., Cook M. Decreased antigen-induced eicosanoid release in conjugated linoleic acid-fed guinea pigs. Am J Physiol Regul Integr Comp Physiol 2002, 282:R1104-R1112.
36. Fuss I., Neurath M., Boirivant M., Klein J., de la Motte C., Strong S., et al. Disparate cd4+ lamina propria (lp) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease lp cells manifest increased secretion of ifn-gamma, whereas ulcerative colitis lp cells manifest increased secretion of il-5. J Immunol 1996, 157:1261-1270.
37. Strober W., Fuss I., Blumberg R. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002, 20:495-549.
38. Hontecillas R., Bassaganya-Riera J. Peroxisome proliferator-activated receptor gamma is required for regulatory cd4+ t cell-mediated protection against colitis. J Immunol 2007, 178:2940-2949.
39. Bassaganya-Riera J., Hontecillas-Magarzo R., Bregendahl K., Wannemuehler M., Zimmerman D. Effects of dietary conjugated linoleic acid in nursery pigs of dirty and clean environments on growth, empty body composition, and immune competence. J Anim Sci 2001, 79:714-721.
40. Nancey S., Hamzaoui N., Moussata D., Graber I., Bienvenu J., Flourie B. Serum interleukin-6, soluble interleukin-6 receptor and crohn's disease activity. Dig Dis Sci 2008, 53:242-247.
41. Lewis J., Lichtenstein G., Stein R., Deren J., Judge T., Fogt F., et al. An open-label trial of the ppar-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001, 96:3323-3328.